Tags : Lasmiditan


Eli Lilly Launches Reyvow (lasmiditan) C-V for the Treatment of

Shots: Eli Lilly launches Reyvow C-V 50/100/200mg, indicated for the acute treatment of migraine with/without aura & will be available in US pharmacies in the next few days The efficacy of the therapy is evaluated in SAMURAI and SPARTAN studies assessing Reyvow vs PBO in 4439 patients with migraine, results demonstrated that patients achieved fast […]Read More


Lilly Files Lasmiditan to FDA for Acute Treatment of Migrane

Shots: •      The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults •     The collective results of the study demonstrated safety and efficacy of Lasmiditan, meeting all 1EP & 2EP, showing greater percentage of patients free of their […]Read More